Monopar Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Monopar Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 05, 2023 | Last Trade: US$39.59 1.57 4.13

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 11 - 13, 2023.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Stock Quote

Last Trade:	US$39.59
Daily Change:	1.57 4.13
Daily Volume:	11,727
Market Cap:	US$241.500M

March 31, 2025 Monopar Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments December 05, 2024 Monopar Therapeutics Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu December 03, 2024 Monopar Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference November 08, 2024 Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments October 28, 2024 Monopar Therapeutics Announces Proposed Public Offering of Common Stock LOAD MORE NEWS

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE